DiviDrip · ZYME

ZYME — Zymeworks Inc.

ZYME is Zymeworks Inc. (Healthcare) — a non-dividend-paying stock. Trading at $29.19. Market cap: $2.09B. Capital Quality Rank: 93/100 — Market alpha.

Stock snapshot

Price$29.19
Market cap$2.09B
SectorHealthcare
ExchangeNMS
Pays dividendNo

Capital Quality & fundamentals

DiviDrip's Capital Analytics engine ranks every non-dividend stock 1-100 on a 4-factor composite (Shareholder Yield 30%, Cash-Flow ROI 25%, Operating Momentum 25%, Tail-Risk 20%) — sector-neutralized so a biotech isn't penalized for negative earnings the way a utility would be.

Capital Quality Rank (1-100)93 / 100 · Market alpha
ROIC (TTM)-32.2%
Revenue CAGR (3y)-36.4%
Shareholder buyback yield0.62%
Altman Z-score zoneSafe

About ZYME

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Listed2017Employees264HQMiddletown, DESectorHealthcareWebsitezymeworks.com

Related non-dividend companies

Other non-dividend stocks investors research alongside ZYME. Peer set from Massive news + returns similarity, filtered to names we currently track.

Frequently asked

What is ZYME's current stock price?

ZYME (Zymeworks Inc.) is currently trading at $29.19.

Does ZYME pay a dividend?

ZYME (Zymeworks Inc.) does not currently pay a regular dividend.

What is ZYME's Capital Quality Rank?

ZYME has a Capital Quality Rank of 93/100 — Market alpha. This score blends ROIC, revenue growth, buybacks, and balance-sheet health.

Track ZYME in DiviDrip

Add ZYME to your watchlist on DiviDrip to monitor price, fundamentals, and Capital Quality Rank week-over-week. Built for long-term investors tracking both dividend and non-dividend names.

Data refreshed 2026-09-05. Not investment advice. Prices change continuously; always verify the latest numbers in the live app before buying.

Related guides

DiviDrip is a free dividend portfolio tracker built by dividend investors, for dividend investors. Try it free — no payment, no upsell, ever. Read the How-To to see how each tool fits together, or browse the Glossary for every term defined plain-English.

Disclaimer: The information provided on this website/service is for informational purposes only and does not constitute financial, investment, or legal advice. Investing in stocks involves high risk, including the loss of principal. We are not responsible for any financial losses or damages resulting from your reliance on this data. Always consult with a qualified financial professional before making investment decisions.

Trademark Notice: Twylight Crow's Dividend Tracker (formerly indexed as DiviDrip) is an independent portfolio utility. This tool is not affiliated with, authorized, endorsed by, or in any way officially connected to Dividrip.com or its international affiliates.

Contact: dividrip@twylightcrow.com© 2026 Twylight Crow